NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
1、“Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder.
2、Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability.
3、Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder
4、Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder
5、Provide one-stop product solution customization service
The main methods of NMNH powder preparation include extraction, fermentation, fortification, biosynthesis and organic matter synthesis. Compared with other preparations, the whole enzyme become the mainstream method owing to the advantages of pollution free, high level of purity and stability.
when applied to cultured cells, the NMNH is shown to be more efficient than NMN as it was able to “significantly increase NAD+ at a ten times lower concentration (5 µM) than that needed for NMN”. Moreover, NMNH shows to be more effective, as at 500 µM concentration, it achieved “an almost 10- fold increase in the NAD+ concentration, while NMN was only able to double NAD+ content in these cells, even at 1 mM concentration.”.
Interestingly, NMNH also appears to act quicker and has a longer-lasting effect compared to NMN. According to the authors, NMNH induces a “significant increase in NAD+ levels within 15 minutes”, and “NAD+ steadily increased for up to 6 hours and remained stable for 24 hours, while NMN reached its plateau after only 1 hour, most likely because the NMN recycling pathways to NAD+ had already become saturated.”.
NMNH also proved more effective than NMN in raising NAD+ levels in a variety of tissues when administered at the same concentration, confirming the results observed in cell lines. The data presented in this study also corroborate the evidence that NAD+ boosters protect against different models of acute kidney injury, and place NMNH as a great alternative intervention to other NAD+ precursors to reduce tubular damage and accelerate recovery.
To overcome the limitations of the current repertoire of NAD+ enhancers, other molecules with a more pronounced effect on the NAD+ intracellular pool are desired. This has stimulated us to investigate the use of the reduced form of nicotinamide mononucleotide (NMNH) as an NAD+ enhancer. There is very scarce information about the role of this molecule in cells. In fact, only one enzymatic activity has been described to produce NMNH. This is the NADH diphosphatase activity of the human peroxisomal Nudix hydrolase hNUDT1232 and the murine mitochondrial Nudt13.33 It has been postulated that, in cells, NMNH would be converted to NADH via nicotinamide mononucleotide adenylyl transferases (NMNATs).34 However, both NMNH production by Nudix diphosphatases and its use by NMNATs for NADH synthesis have only been described in vitro using isolated proteins, and how NMNH participates in cellular NAD+ metabolism remains unknown.
First, inspect the factory. After some screening, NMNH companies that directly face consumers pay more attention to brand building. Therefore, for a good brand, quality is the most important thing, and the first thing to control the quality of raw materials is to inspect the factory. Bontac company actually manufacturing NMNH powder of high quality with the caterias of SGS. Secondly, the purity is tested. Purity is one of the most important parameters of NMN powder. If high purity NMNH cannot be guaranteed, the remaining substances are likely to exceed the relevant standards. As the attached certificates demonstrates that the NMNH powder produced by Bontac reach the purity of 99%. Finally, a professional test spectrum is needed to prove it. Common methods for determining the structure of an organic compound include Nuclear Magnetic Resonance Spectroscopy (NMR) and high-resolution mass spectrometry (HRMS). Usually through the analysis of these two spectra, the structure of the compound can be preliminarily determined.
1. Introduction Nicotinamide adenine dinucleotide (NAD) compartmentalized in adipocytes can modulate adipocyte differentiation and gene expression, in addition to controlling glucose metabolism. White adipose tissue (WAT), one major adipose tissue, may be one of the direct target for NAD supplementation. 2. About WAT In contrast to brown adipose tissue (BAT), WAT contains a single lipid droplet and few mitochondria. WAT, once thought to be morphologically and functionally unremarkable, is in fact highly dynamic, with plasticity and heterogeneity, which is widely distributed in the subcutaneous tissues and around the internal organs. WAT plays a key role in a range of biological processes, such as maintenance of energetic homeostasis, processing and handling of glycans and lipids, blood pressure control, and host defence, with tight relationship with metabolic disorders such as diabetes. 3. The tissue-specific roles of NAD NMN is synthesized from NAM and NR by NAMPT and NRK, respectively. The synthesized NAD+ from NMN is used as a SIRT1 substrate, which leads to the recycling of NAD+ via the salvage pathway. In this process, NAD+ can exert different effects depending on the tissue. Remarkably, NAD precursors can control metabolic stress particularly via focusing on adipose tissue. 4. The effects of boosting NAD+ on WAT Supplementation of NMN and NR has been shown to reduce body weight and enhance insulin sensitivity in regular chow-fed aged wild-type mice and diet-induced obese mice, respectively. NAM supplementation diminishes fat accumulation in diet-induced obese mice. Additionally, both NMN and NR supplementation prevent inflammation even with different treatment duration. NAM administration boosts mitochondrial biogenesis and glutathione synthesis in WAT. Similarly, it is evidenced that NMN treatment in high fat diet-induced type 2 diabetes mouse model facilitates the recovery of Glutathione S-transferase Alpha 2 (Gsta2) gene expression in the liver. 5. The adipose-specific effects of nicotinamide phosphoribosyltransferase (NAMPT) NAMPT, one NAD regulator in WAT, is a promising therapeutic target for the treatment of metabolic disorders. NAMPT plays a potential role in maintaining adipose tissue homoeostasis, as evidenced by the explicitly blocked adipocyte differentiation and lipid synthesis in vitro post treatment of NAMPT inhibitor FK866. For some reasons such as differences in sex, age, and/or basal levels of cellular NAD+ availability, there are various inconclusive results regarding the impacts of NAD+ metabolism on adipocytes in the adipocyte-specific NAMPT-deficient mouse model or in vitro cell models. Further investigation on the effects of NAD+ supplementation and the distinct functions of NAMPT in adipocytes is still needed. 6. Conclusion The importance of NAD metabolism in WAT has been highlighted. NAD has tissue-specific roles. Specifically, WAT may be one of the direct target for NAD supplementation. Supplementation with NAD+ precursors can reduce fat accumulation and inflammation in adipose tissue. Reference Kwon SY, Park YJ. Function of NAD metabolism in white adipose tissue: lessons from mouse models. Adipocyte. 2024;13(1):2313297. doi:10.1080/21623945.2024.2313297 About BONTAC BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team consisting of Doctors and Masters. BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and its precursors (eg. NMN and NR), with various forms to be selected (eg. endoxin-free IVD-grade NAD, Na-free or Na-containing NAD; NR-CL or NR-Malate). High quality and stable supply of products can be better ensured here with the exclusive Bonpure seven-step purification technology and Bonzyme Whole-enzymatic method. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
Introduction Natural products, including single components or extracts of herbal medicines, have the features of good efficacy and low toxicity when used in tumor treatment. They have unique advantages in treating diseases compared with chemotherapeutic drugs due to their multi-component and multi-target effects. Strikingly, ginsenoside Rg3-loaded PLGA nanoparticles (Rg3-PLGA) coated with the membrane of tumor cell-derived microvesicles (Rg3-PLGA@TMVs), which is a nanoformulation of the natural product ginsenoside Rg3, have a significant role in the treatment of breast cancer when combined with the chemotherapeutic drug doxorubicin (DOX). Pharmacological roles of ginseng Rg3 in traditional Chinese medicine Ginseng Rg3, a tetracyclic triterpenoid saponin, is one of the main active component of ginseng. Ginseng has been regarded as one of the most valuable medicinal plants in Chinese traditional medicine for thousands of years, which is known as "the king of all tonic”. This perennial herb possesses the multiple pharmaceutical functions such as tonifying the vital energy, restoring the pulse and stabilizing the loss of vitality, invigorating spleen and benefiting lung, generating saliva or body fluid to quench thirst, as well as tranquilizing the mind and promoting the intelligence. The construction of Rg3-PLGA@TMVs Ginsenoside Rg3 is first encapsulated into PLGA nanoparticles using the nanoprecipitation method, followed by the extrusion-based coating of the TMV membrane onto Rg3-PLGA. This strategy combines the therapeutic properties of Rg3 with the precise delivery and sustained release capabilities of PLGA nanoparticles, further enhanced by the homologous targeting properties of TMVs. Anti-tumor effect and bio-safety of Rg3-PLGA@TMVs in 4T1 breast cancer Rg3-PLGA@TMVs induce robust anti-tumor immunity, recover the body weight loss caused by DOX in 4T1 breast cancer and overtly improve the anti-tumor effect of DOX, showing good stability and drug loading capability. These anti-tumor effects are chiefly realized by reducing phagocytic activity and acid phosphatase (ACP) levels, promoting the maturation of bone marrow-derived dendritic cells in vitro, and elevating the population of cytotoxic T lymphocytes (CD3+CD8+) and helper T cells (CD3+CD4+) in vivo. Importantly, this nanoformulation has minimal side effects and favorable biocompatibility, which can relieve the organ toxicity caused by DOX, especially the cardiac side effects. The administration of DOX and Rg3-PLGA@TMVs does not result in statistically significant changes in white blood cell (WBC) count and renal functional indicators, such as CREA and urea, nor in hepatic functional indicators, including AST and ALT. Conclusion Rg3-PLGA@TMVs achieve the co-delivery of antigens and adjuvants, which not only potentiate the anti-tumor effects, but also significantly alleviate the systemic toxicity caused by chemotherapeutic drugs, improving the overall health status of patients undergoing chemotherapy. Reference [1] Liu XR, Zhang KF, Li X, et al. Research progress on antitumor nanoscale drug delivery system of ginsenoside Rg3 [J]. Chin Trad Herb Drugs. 2023,54(22):7577-7587. DOI: 10.7501/j.issn.0253-2670.2023.22.034 [2]Zhang S, Zheng B, Wei Y, et al. Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviate toxicity [J]. Biomater Sci. Published online April 10, 2024. DOI:10.1039/d4bm00159a BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). With unique Bonzyme enzymatic synthesis technology, both S-type and R-type isomers can be accurately synthesized here, with stronger activity and precise targeting action. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.
Introduction Elderly individuals are at a significantly higher risk for peripheral artery disease (PAD), a common vascular disorder. As the global population ages rapidly, the number of PAD cases is projected to rise further. People with PAD have increased oxidative stress, damaged skeletal muscle fibers, impaired mitochondrial activity, and poor walking performance, showing a high risk of cardiovascular and cerebrovascular events. Recently, a NICE randomized clinical trial uncovers that supplementation of nicotinamide riboside (NR) can improve the walking ability of PAD patients, opening up new opportunities for the treatment of PAD. About PAD PAD is a chronic atherosclerosis disease in which stenoses or occlusions of the peripheral arteries result in insufficient blood flow/oxygen/nutrient delivery to the distal extremity, with the typical symptoms such as ischemic rest pain, numbness of extremity, intermittent claudication and weakness of body. Herein, the testing criteria of PAD are determined as follow: a toe brachial index < 0.70, ankle brachial index (ABI) ≤ 0.90, 70% or greater stenosis in a lower extremity artery on Duplex testing, or a post-exercise ABI decline of at least 20%. The potential significance of replenishing NR in PAD As previous research demonstrated, oral administration of NR to boost NAD+ abundance can promote skeletal muscle SIRT1 expression, mitochondrial activity, limb strength as well as running endurance, activate endothelial nitric oxide synthase (eNOS) and reduce oxidative stress to increase the abundance of nitric oxide, a key vasodilator that can relax blood vessels and maintain their elasticity. All of these effects delivered by NR are contributive to the improvement of PAD. Research protocol 90 participants with PAD are randomly allocated into NR+resveratrol, NR+placebo, and placebo+placebo groups, and then are asked to take five pills daily for 6 months, including two 250 mg of NR pills (or placebo) twice daily and one 125 mg resveratrol (or placebo) once daily, followed by 3-month and 6-month follow-up. NR's impact on 6-minute walk in PAD NR meaningfully improves 6-min walk, and no added advantage is observed from resveratrol. Specifically, among participants who take at least 75% of study pills, NR improves 6-min walk by 31.0 meters and NR + resveratrol promote 6-min walk by 26.9 meters, as compared with placebo. In addition, NR increases satellite cell abundance in gastrocnemius muscle, compared to placebo, but does not affect muscle fiber type. Moreover, people randomized to NR + resveratrol report higher rates of diarrhea and higher rates of nausea or emesis, compared to those randomized to NR alone or placebo. Conclusion Supplementation of NR, to some exert, has shown potential to enhance walking performance in PAD patients. This NICE randomized clinical trial lays a preliminary foundation in establishing the feasibility of NR as a therapeutic intervention for PAD. Reference [1] Khan NA, Auranen M, Paetau I, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med. 2014;6(6):721-731. doi:10.1002/emmm.201403943 [2] Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. Published 2018 Mar 29. doi:10.1038/s41467-018-03421-7 [3] McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15(1):5046. Published 2024 Jun 13. doi:10.1038/s41467-024-49092-5 [4] Zhang H, Ryu D, Wu Y, et al. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443. doi:10.1126/science.aaf2693 BONTAC NR BONTAC is one of the few suppliers in China that can launch mass production of raw materials for NR, with self-owned factory and professional R&D team. Up till now, there are 180+ BONTAC patents. BONTAC provides one-stop service for customized products. Both malate and chloride salt forms of NR are available. By dirt of unique Bonpure seven-step purification technology and Bonzyme whole-enzymatic method, the product content and conversion rate can be maintained in a higher level. The purity of BONTAC NR can reach above 97%. Our products are subjected to strict third-party self-inspection, which are worth of trustworthy. Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.